The Chinese Patent Office issued a notice of acceptance to Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) for a patent application about its multi-wavelength photodynamic therapy (PDT).
The patent validates the proprietary position of the company and opens opportunities for the application of its PDT technology in an international market.
In a statement, Kipton Lade, CEO of Theralase’s device division, said the new multi-wavelength laser system is the latest addition to the company’s technology platform, allowing activation of PDTs at various wavelengths, sequentially or simultaneously, to destroy cancerous targets at correspondingly different tissue depths.
“Our long-term strategy is to commercialize the ACT technology to provide an alternative treatment option for patients inflicted with this deadly disease,” he added. “The ability to provide personalized ACT treatment for cancer patients to destroy their cancer permanently and prevent its recurrence, all in a single treatment, remains at the forefront of our minds.”
China is the fourth largest medical device market in the world behind the USA, Japan and Germany and “represents a new opportunity for Theralase and its expanding platform of technologies,” Mr. Lade said.
